Return News

Lifang & Partners Welcomes the Leading Professional of Pharmaceutical and Biochemical Patent Field, Dr. Wu Li, and his Team

Release time:2022-06-14

In June 2022, on the occasion of the 20th anniversary of the founding of Lifang & Partners, we are pleased to welcome Dr.Wu Li, who is the leading professional of the pharmaceutical and biochemical patent field, and his team members Dr.Wang Rui, Dr.Wu Runzhi, Dr.Yang Jian and Miss.Sun Qi to Lifang & Partners. They mainly work for the Beijing office and Shanghai office.


Wu Li

Senior Partner


J.D., Columbia Law School

Ph.D. in Neuroscience, Columbia University

M.S. in Neuroscience, Chinese Academy of Sciences

B.S. in Biology, Najing University

Dr. Li Wu is an attorney at law and patent attorney qualified to practice in both China and the United States.  His practices cover all aspects of intellectual property law.  He mainly focuses on providing full spectrum of patent services to the clients, including patent prosecution, invalidation and litigation.  Furthermore, he is also very experienced in helping clients set up their global IP protection and enforcement strategy, in particularly concerning their complex and advanced technology. Likewise, he regularly represents clients in matters arising from patent infringement, trade secret misappropriation and technology transfer.

As a private practitioner, Dr. Wu had worked as patent attorney in leading law firms in both China and the United States, serving clients including many MNCs.  In addition, Dr. Wu had also served as in-house counsel for a multinational pharmaceutical company for their IP related matters.

Before starting his legal career, Dr. Wu had worked as a scientist in the field of neuroscience for more than 10 years, and his work on the regulation of calcium channels has been selected and published by the world-famous scientific magazine Nature (Vol. 419:947-952).



Senior Counsel


Ph.D. in Biochemistry, Hong Kong University of Science and Technology

B.S. in Biochemistry, Hong Kong University of Science and Technology

Dr. Rui Wang has solid knowledge background and tremendous rich experience in the fields of molecular biology, cell biology, biochemistry, pharmacy and Chinese medicine. She has rich expertise in patent drafting, prosecution, invalidation and litigation before the Chinese Patent Office and the courts, and frequently advises on freedom-to-operate analysis and patentability analysis for many companies.

Dr. Wang has handled dozens of patent invalidation, patent infringement litigation and administrative treatment of patent infringement, and is highly trusted by clients.

Prior to admitting to practice IP law, Dr. Wang worked as a scientist in many significant research projects supported by the National Natural Science Funding of China, and was awarded the National Natural Science Funding of China for young scientists.


WU Runzhi

Senior Counsel

Dr. Runzhi Wu has research background and 9 years of IP practice experience. She is able to quickly and accurately understand technical solutions and make legal analysis, and she can independently provide legal service regarding patent drafting, legal consultation, patent infringement dispute and patent invalidation.

Dr. Runzhi Wu is specialized in chemical industry, medicinal chemistry, medical equipment, and she has advised multiple transnational corporations (e.g., Umicore, Merck, 3M, Schott, Exxon Mobile, Google) on patent filing, patent analysis, patent invalidation and patent litigation.

Prior to admitting to practice IP law, Dr. Runzhi Wu had been involved in the research of novel antiviral agents and fluorescent molecular probes, having several articles published in the relevant core international academic journals.



Senior Counsel

Dr. Yang has drafted hundreds of Chinese and PCT applications in the fields of biopharmaceuticals, chemistry and chemical engineering. Dr. Yang is familiar with the patent practice in the United States, Europe, Japan, Korea, Australia and other countries, and has been responsible for patent prosecution in about 20 countries or regions.

Dr. Jian Yang is specialized in the fields of biotechnology and pharmaceuticals, especially in tumor biology and immunology, and has rich experience in patent search, patent drafting, patent stability analysis and FTO analysis. Dr. Yang once worked in a leading law firm. Before that, she had been involved in the research of novel tumor markers and anti-tumor vascular drug, having several articles published in the relevant core international academic journals.

Dr. Yang has conducted IP DD analysis for CBridge Capital group, CITIC Private Equity Funds Management Co., Ltd, Shanshan Medical Investment Management (Shanghai) Co., Ltd, Everest Pharmaceutical Technology Co., Ltd., WuXi AppTec Group, and other large domestic listed pharmaceutical companies or startups.




Ms. Sun specializes in patent invalidation, patent litigation and trademark prosecution.

Ms. Sun has been focusing on patent related dispute resolution, including patent litigations, invalidations and patent enforcement actions. She also handled a number of IP related non-contentious issues.


Dr. Wu Li said: “My team and I are very happy to join Lifang & Partners! In the future, we will work to highly integrate into and synthesize with Lifang & Partners' patent application team, patent litigation team, capital market team and compliance team, so as to give full play to our technical advantages in the field of biomedical industry, and match customers with insightful understanding of industrial needs and more comprehensive professional legal services! ”

Lifang & Partners warmly welcomes Dr. Wu Li, Dr.Wang Rui, Dr.Wu Runzhi, Dr.Yang Jian and Miss.Sun Qi! They will breathe new life into Lifang & Partners’ business expansion in the fields of biomedicine, chemical engineering and medical devices, greatly improving Lifang & Partners’ ability to provide relevant legal services in these fields, and helping Lifang & Partners continuously provide customers with added value and high-quality services.

Copyright © 2020      Lifang Partners    京ICP备09037220号-1      京公网安备11010102000452号